Ixekizumab for treating axial spondyloarthritis: Final appraisal document

DRAFT guidance recommends use in adults with active ankylosing spondylitis not well controlled well with conventional therapy, or active non-radiographic axial spondyloarthritis with signs of inflammation, not well controlled with NSAIDs, only if TNFi’s not suitable/not effective

Source:

National Institute for Health and Care Excellence